Clinical application of positron emission tomography/computed tomography in detecting hibernating myocardium_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

LIU Donghui ,  LIU Hongyu

Department of Cardiovascular Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, 150001, P.R.China;

Corresponding?author：

LIU Hongyu, Email: hyliu1963@163.com

Keywords：

Positron emission tomography/computed tomography; hibernating myocardium; revascularization therapy

DOI：

10.7507/1007-4848.201811060

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

With the in-depth study of the pathophysiological changes of ischemic myocardium, some experimental studies have found that in many patients with coronary heart disease, severe lesions and long duration of diseases which do not recover due to revascularization, are mainly related to the viable myocardium in the affected area. Survival myocardium refers to those perfusion defect-induced dysfunctional but not dead cardiomyocytes, including stunned myocardium and hibernating myocardium. Therefore, accurate assessment of viable myocardium is important for the development of clinical treatment options and prognosis assessment of such patients. Positron emission tomography/computed tomography (PET/CT) can evaluate the survival of hibernating myocardium and quantitatively analyze it. Thus PET/CT can provide useful information for the possibility of myocardial function recovery after revascularization, treatment options and prognosis evaluation.

Citation： LIU Donghui, LIU Hongyu. Clinical application of positron emission tomography/computed tomography in detecting hibernating myocardium. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2019, 26(9): 916-919. doi: 10.7507/1007-4848.201811060 Copy

1.	Rees G, Bristow JD, Kremkau EL, et al. Influence of aortocoronary bypass surgery on left ventricular performance. N Engl J Med, 1971, 284(20): 1116-1120.
2.	Sarikaya I. Cardiac applications of PET. Nucl Med Commun, 2015, 36(10): 971-985.
3.	Baker JE, Su J, Hsu A, et al. Human thrombopoietin reduces myocardial infarct size, apoptosis, and stunning following ischaemia/reperfusion in rats. Cardiovasc Res, 2008, 77(1): 44-53.
4.	H?yer C, Aagaard SR, Pedersen TF, et al. Apical myocardial stunning in a large size porcine model assessed by strain and strain rate echocardiography. Echocardiography, 2007, 24(9): 923-932.
5.	Mollerus M, Naslund L. Myocardial stunning following defibrillation threshold testing. J Interv Card Electrophysiol, 2007, 19(3): 213-216.
6.	Brendt P, Behrends M, Peters J. Myocardial stunning following no flow ischaemia is diminished by levosimendan or cariporide, without benefits of combined administration. Resuscitation, 2008, 76(1): 95-102.
7.	Parasher PS, Daher IN. Myocardial recovery after hypoxia: stunning recovery. Echocardiography, 2008, 25(9): 1011-1013.
8.	Mahmoud H, Forni LG, McIntyre CW, et al. Myocardial stunning occurs during intermittent haemodialysis for acute kidney injury. Intensive Care Med, 2017, 43(6): 942-944.
9.	顏姝. 心肌頓抑的防治機制新進展. 中國動脈硬化雜志, 2013, 21(12): 1149-1152.
10.	胡旭東. 心肌頓抑和冬眠的臨床意義及機制. 中華內科雜志, 1996, 35(6): 7.
11.	劉金來, 張書剛. 冬眠心肌檢測方法的評價. 國際內科學雜志, 2000, 27(1): 25-27.
12.	任臻, 鐘栩. 心肌細胞能量代謝障礙及藥物治療研究進展. 中醫臨床研究, 2016, 8(35): 51-54.
13.	宋濤, 李臣文, 趙文秀, 等. 心肌缺血的能量代謝及代謝藥物治療. 實用心腦肺血管病雜志, 2006, 14(10): 766-768.
14.	Wong CY, Tatini VR, Bis K. Combined CT-PET criteria for myocardial viability and scar: a preliminary report. Int J Cardiovasc Imaging, 2004, 20(6): 487-491.
15.	Schinkel AF, Bax JJ, Poldermans D, et al. Hibernating myocardium: diagnosis and patient outcomes. Curr Probl Cardiol, 2007, 32(7): 375-410.
16.	胡紅波, 邵高峰, 丘志芬. 一種PET/CT呼吸門控系統的設計. 醫療衛生裝備, 2016, 37(2): 29-31.
17.	Brunken RC, Mody FV, Hawkins RA, et al. Persistent twenty-four hour SPECT thallium-201 defects, plasma thallium-201 concentrations and PET metabolic viability. Herz, 1994, 19(1): 28-41.
18.	Patterson RE, Sigman SR, O'Donnell RE, et al. Viability assessment with MRI is superior to FDG-PET for viability: Con. J Nucl Cardiol, 2010, 17(2): 298-309.
19.	Yoshida K, Gould KL. Quantitative relation of myocardial infarct size and myocardial viability by positron emission tomography to left ventricular ejection fraction and 3-year mortality with and without revascularization. J Am Coll Cardiol, 1993, 22(4): 984-997.
20.	Tian M, Koyama K, Zhang H, et al. Assessment of myocardial viability with a positron coincidence gamma camera using fluorodeoxyglucose in comparison with dedicated PET. Nucl Med Commun, 2003, 24(4): 367-374.
21.	Allman KC, Shaw LJ, Hachamovitch R, et al. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol, 2002, 39(7): 1151-1158.
22.	Beanlands RS, Nichol G, Huszti E, et al. F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2). J Am Coll Cardiol, 2007, 50(20): 2002-2012.
23.	Abraham A, Nichol G, Williams KA, et al. 18F-FDG PET imaging of myocardial viability in an experienced center with access to 18F-FDG and integration with clinical management teams: the Ottawa-FIVE substudy of the PARR 2 trial. J Nucl Med, 2010, 51(4): 567-574.
24.	D'Egidio G, Nichol G, Williams KA, et al. Increasing benefit from revascularization is associated with increasing amounts of myocardial hibernation: a substudy of the PARR-2 trial. JACC Cardiovasc Imaging, 2009, 2(9): 1060-1068.
25.	Ling LF, Marwick TH, Flores DR, et al. Identification of therapeutic benefit from revascularization in patients with left ventricular systolic dysfunction: inducible ischemia versus hibernating myocardium. Circ Cardiovasc Imaging, 2013, 6(3): 363-372.
26.	孫茉茉, 李劍明, 等. 冠狀動脈旁路移植術前13N-NH3/18f-FDGPET顯像檢測冬眠心肌的臨床研究. 中國醫學影像技術, 2018, 34(7): 1003-1008.
27.	任少陽, 侯先存, 周青, 等. 雙核素心肌灌注-代謝顯像評價存活心肌對心肌梗死患者擇期血運重建術后左心功能的影響. 中華核醫學雜志, 2011, 31(3): 169-173.
28.	Partington SL, Kwong RY, Dorbala S. Multimodality imaging in the assessment of myocardial viability. Heart Fail Rev, 2011, 16(4): 381-395.
29.	Perrone-Filardi P, Pinto FJ. Looking for myocardial viability after a STICH trial: not enough to close the door. J Nucl Med, 2012, 53(3): 349-352.
30.	Bonow RO, Maurer G, Lee KL, et al. Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med, 2011, 364(17): 1617-1625.
31.	Schinkel AF, Poldermans D, Vanoverschelde JL, et al. Incidence of recovery of contractile function following revascularization in patients with ischemic left ventricular dysfunction. Am J Cardiol, 2004, 93(1): 14-17.
32.	Inaba Y, Chen JA, Bergmann SR. Quantity of viable myocardium required to improve survival with revascularization in patients with ischemic cardiomyopathy: A meta-analysis. J Nucl Cardiol, 2010, 17(4): 646-654.
33.	Desideri A, Cortigiani L, Christen AI, et al. The extent of perfusion-F18-fluorodeoxyglucose positron emission tomography mismatch determines mortality in medically treated patients with chronic ischemic left ventricular dysfunction. J Am Coll Cardiol, 2005, 46(7): 1264-1269.
34.	李東野. 存活心肌檢測對冠心病血運重建治療決策的影響. 中華臨床醫師雜志(電子版), 2009, 3(7): 1094-1099.

1. Rees G, Bristow JD, Kremkau EL, et al. Influence of aortocoronary bypass surgery on left ventricular performance. N Engl J Med, 1971, 284(20): 1116-1120.
2. Sarikaya I. Cardiac applications of PET. Nucl Med Commun, 2015, 36(10): 971-985.
3. Baker JE, Su J, Hsu A, et al. Human thrombopoietin reduces myocardial infarct size, apoptosis, and stunning following ischaemia/reperfusion in rats. Cardiovasc Res, 2008, 77(1): 44-53.
4. H?yer C, Aagaard SR, Pedersen TF, et al. Apical myocardial stunning in a large size porcine model assessed by strain and strain rate echocardiography. Echocardiography, 2007, 24(9): 923-932.
5. Mollerus M, Naslund L. Myocardial stunning following defibrillation threshold testing. J Interv Card Electrophysiol, 2007, 19(3): 213-216.
6. Brendt P, Behrends M, Peters J. Myocardial stunning following no flow ischaemia is diminished by levosimendan or cariporide, without benefits of combined administration. Resuscitation, 2008, 76(1): 95-102.
7. Parasher PS, Daher IN. Myocardial recovery after hypoxia: stunning recovery. Echocardiography, 2008, 25(9): 1011-1013.
8. Mahmoud H, Forni LG, McIntyre CW, et al. Myocardial stunning occurs during intermittent haemodialysis for acute kidney injury. Intensive Care Med, 2017, 43(6): 942-944.
9. 顏姝. 心肌頓抑的防治機制新進展. 中國動脈硬化雜志, 2013, 21(12): 1149-1152.
10. 胡旭東. 心肌頓抑和冬眠的臨床意義及機制. 中華內科雜志, 1996, 35(6): 7.
11. 劉金來, 張書剛. 冬眠心肌檢測方法的評價. 國際內科學雜志, 2000, 27(1): 25-27.
12. 任臻, 鐘栩. 心肌細胞能量代謝障礙及藥物治療研究進展. 中醫臨床研究, 2016, 8(35): 51-54.
13. 宋濤, 李臣文, 趙文秀, 等. 心肌缺血的能量代謝及代謝藥物治療. 實用心腦肺血管病雜志, 2006, 14(10): 766-768.
14. Wong CY, Tatini VR, Bis K. Combined CT-PET criteria for myocardial viability and scar: a preliminary report. Int J Cardiovasc Imaging, 2004, 20(6): 487-491.
15. Schinkel AF, Bax JJ, Poldermans D, et al. Hibernating myocardium: diagnosis and patient outcomes. Curr Probl Cardiol, 2007, 32(7): 375-410.
16. 胡紅波, 邵高峰, 丘志芬. 一種PET/CT呼吸門控系統的設計. 醫療衛生裝備, 2016, 37(2): 29-31.
17. Brunken RC, Mody FV, Hawkins RA, et al. Persistent twenty-four hour SPECT thallium-201 defects, plasma thallium-201 concentrations and PET metabolic viability. Herz, 1994, 19(1): 28-41.
18. Patterson RE, Sigman SR, O'Donnell RE, et al. Viability assessment with MRI is superior to FDG-PET for viability: Con. J Nucl Cardiol, 2010, 17(2): 298-309.
19. Yoshida K, Gould KL. Quantitative relation of myocardial infarct size and myocardial viability by positron emission tomography to left ventricular ejection fraction and 3-year mortality with and without revascularization. J Am Coll Cardiol, 1993, 22(4): 984-997.
20. Tian M, Koyama K, Zhang H, et al. Assessment of myocardial viability with a positron coincidence gamma camera using fluorodeoxyglucose in comparison with dedicated PET. Nucl Med Commun, 2003, 24(4): 367-374.
21. Allman KC, Shaw LJ, Hachamovitch R, et al. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol, 2002, 39(7): 1151-1158.
22. Beanlands RS, Nichol G, Huszti E, et al. F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2). J Am Coll Cardiol, 2007, 50(20): 2002-2012.
23. Abraham A, Nichol G, Williams KA, et al. 18F-FDG PET imaging of myocardial viability in an experienced center with access to 18F-FDG and integration with clinical management teams: the Ottawa-FIVE substudy of the PARR 2 trial. J Nucl Med, 2010, 51(4): 567-574.
24. D'Egidio G, Nichol G, Williams KA, et al. Increasing benefit from revascularization is associated with increasing amounts of myocardial hibernation: a substudy of the PARR-2 trial. JACC Cardiovasc Imaging, 2009, 2(9): 1060-1068.
25. Ling LF, Marwick TH, Flores DR, et al. Identification of therapeutic benefit from revascularization in patients with left ventricular systolic dysfunction: inducible ischemia versus hibernating myocardium. Circ Cardiovasc Imaging, 2013, 6(3): 363-372.
26. 孫茉茉, 李劍明, 等. 冠狀動脈旁路移植術前13N-NH3/18f-FDGPET顯像檢測冬眠心肌的臨床研究. 中國醫學影像技術, 2018, 34(7): 1003-1008.
27. 任少陽, 侯先存, 周青, 等. 雙核素心肌灌注-代謝顯像評價存活心肌對心肌梗死患者擇期血運重建術后左心功能的影響. 中華核醫學雜志, 2011, 31(3): 169-173.
28. Partington SL, Kwong RY, Dorbala S. Multimodality imaging in the assessment of myocardial viability. Heart Fail Rev, 2011, 16(4): 381-395.
29. Perrone-Filardi P, Pinto FJ. Looking for myocardial viability after a STICH trial: not enough to close the door. J Nucl Med, 2012, 53(3): 349-352.
30. Bonow RO, Maurer G, Lee KL, et al. Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med, 2011, 364(17): 1617-1625.
31. Schinkel AF, Poldermans D, Vanoverschelde JL, et al. Incidence of recovery of contractile function following revascularization in patients with ischemic left ventricular dysfunction. Am J Cardiol, 2004, 93(1): 14-17.
32. Inaba Y, Chen JA, Bergmann SR. Quantity of viable myocardium required to improve survival with revascularization in patients with ischemic cardiomyopathy: A meta-analysis. J Nucl Cardiol, 2010, 17(4): 646-654.
33. Desideri A, Cortigiani L, Christen AI, et al. The extent of perfusion-F18-fluorodeoxyglucose positron emission tomography mismatch determines mortality in medically treated patients with chronic ischemic left ventricular dysfunction. J Am Coll Cardiol, 2005, 46(7): 1264-1269.
34. 李東野. 存活心肌檢測對冠心病血運重建治療決策的影響. 中華臨床醫師雜志(電子版), 2009, 3(7): 1094-1099.

Previous Article
Current status of early cardiac rehabilitation management after cardiac surgery in China
Next Article
Current research status of Tibetan lung cancers

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Clinical application of positron emission tomography/computed tomography in detecting hibernating myocardium

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content